Issue Date: January 28, 2008
Toward Greener Therapeutic Proteins
THE PHARMACEUTICAL industry is making great strides in developing cleaner and more efficient syntheses—that is, greener chemistry—for manufacturing small-molecule drugs. But how green are manufacturing processes for biopharmaceuticals, such as monoclonal antibodies, peptide hormones, and vaccines? And can those processes be greener?
Those are questions Sa V. Ho and colleagues at Pfizer's Global Biologics unit, based in Chesterfield, Mo., are trying to answer. The researchers have set out to determine the type and amount . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society